Lymphoma, Solid Tumor
Conditions
Keywords
IMC-002, Phase I, CD47, SIRPα
Brief summary
This is the first-in-human, Phase I, open-label, multiple-ascending dose study to investigate the safety, tolerability, PK, PharmDyn, and clinical activity of IMC-002 in subjects with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas. Male or female subjects 18 years and older with metastatic or locally advanced solid tumors and relapsed or refractory lymphomas will be included in the study if they meet all the inclusion criteria and none of the exclusion criteria. The study will consist of 2 parts: Part 1: Dose Escalation Part 2: Expansion Cohorts
Detailed description
Part 1: Dose Escalation Part 2: Expansion Cohort The study may be amended in the future to include expansion cohorts in selected tumor types to further evaluate extended safety of IMC-002 at recommended Phase 2 dose in that tumor type. Sample size in the Dose Expansion part will be determined when the study is amended to include the expansion cohorts.
Interventions
BIOLOGICALIMC-002
IMC-002 blocks the interaction between CD47 and SIRPα.
Sponsors
ImmuneOncia Therapeutics Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Dose escalation will consist of two distinct sub-parts (1A and 1B).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Subjects are eligible to be included in the study only if all of the following criteria apply: 1. Signed informed consent form (ICF) 2. Adult (18 years or older) 3. Histologically or cytologically proven metastatic or locally advanced solid tumors and relapsed or refractory lymphomas, for which no standard therapy known to prolong survival exists or have relapsed/refractory/PD following the last line of treatment 4. Solid tumors must be measurable with at least 1 unidimensional measurable lesion by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Lymphomas must have at least 1 measurable lesion according to the Lugano criteria with the Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) modification 5. Availability of tumor archival material or fresh biopsies for measurement of CD47 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at Screening and an estimated life expectancy of at least 3 months 7. Adequate hematologic function, hepatic function, and renal function
Exclusion criteria
Subjects are excluded from the study if any of the following criteria apply: 1. Treatment with nonpermitted drugs (within 28 days before Day 1). 2. Prior treatment with a CD47 or SIRPα targeting agent 3. Concurrent anticancer treatments within 28 days before Day 1/first study treatment administration 4. Major surgery or significant traumatic injury within 6 weeks prior to Screening or planned major surgery during the study period 5. Previous malignant disease other than the target malignancy for this study, except adequately treated Stage I or II cancers from which the subject is currently in complete remission per the Investigator's clinical judgment 6. Primary central nervous system (CNS) disease or leptomeningeal disease; known CNS metastases unless treated 7. Comorbidities/medical history of any significant diseases that in the judgment of the Investigator would make the subject inappropriate for this study 8. Active infection requiring systemic therapy within 14 days before Day 1 9. Persisting toxicities Grade \> 1 NCI-CTCAE Version 5.0 related to prior anticancer treatment 10. Pregnant or lactating
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of dose-limiting toxicities (DLT) | For 28 days |
| Incidence and severity of adverse events (AEs) | 2 years |
Countries
South Korea, United States
Outcome results
None listed